Get to “Nose”: Part 2 – Individualizing Treatment for Chronic Rhinosinusitis with Nasal Polyps: Novel Options for Optimizing Outcomes – Clinical Review

Released On
December 17, 2021

Expires On
December 17, 2022

Media Type

Completion Time
30 minutes

Allergy & Immunology, Primary Care


Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Horizon CME.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals Inc. and Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 0.50 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.


Target Audience

Physician specialists (allergists, immunologists, ENTs) and primary care providers who may treat patients with CRSwNP.

Program Overview

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic condition associated with multiple comorbidities and decreased quality of life. It is a condition characterized by inflammation of the sinonasal mucosa and clinical symptoms including blocked nose, rhinorrhea, hyposmia or anosmia, and pain or pressure in the face. Advances in understanding of the underlying pathology for CRSwNP has resulted in novel immunomodulatory biologic therapies for its treatment.

In the second of a 2-part series, this text-based activity will offer learners an in-depth review of the clinical data with biologic therapies for the treatment of CRSwNP.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Evaluate the mechanism of action, safety, and efficacy of biologics for the treatment of chronic rhinosinusitis with nasal polyps


Anju Tripathi Peters, MD, MS

Professor, Department of Medicine
Director of Clinical Research, Division of Allergy-Immunology
Northwestern University Feinberg School of Medicine
Chicago, IL

Accreditation Statement

Horizon CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Horizon CME designates this enduring activity for a maximum of 0.50 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Disclosures of Conflicts of Interest

Horizon CME requires all planners, faculty, and other contributors to disclose any financial relationships with an ACCME defined ineligible company within the past 24 months and Horizon CME has resolved any conflicts prior to this educational activity.


Anju Tripathi Peters, MD, MS
  • Research Funding: AstraZeneca, Optinose, Sanofi Regeneron
  • Advisory Board: AstraZeneca, Sanofi Regeneron
  • Consultant: GSK, Optinose

Planners and Reviewers

Brian Lee, PharmD: Has no relevant relationships.

Tyler Yates, MD: Has no relevant relationships

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  • Read the CME/CE information, learning objectives, and faculty disclosures
  • Complete the Pre-Test
  • Participate in the Activity
  • Score 75% on the post-test
  • Complete the Evaluation form
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

Horizon CME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions please contact:

Statement of Independence

Per ACCME, AMA and FDA regulations, it is understood that commercial supporters will have no influence on the content of the activity. Horizon CME will ensure an unbiased presentation and provide full disclosure of relationships between Horizon CME and all commercial supporters and any significant financial interest or other relationship between faculty and manufacturers of commercial products discussed in the activities. No faculty proposed in this grant is an employee, shareholder, owner, or has financial interest in the accrediting power. It is understood that commercial support funding of this activity is not in any way conditioned upon any present or future business relationship.

Copyright Information

Copyright © 2021 by Horizon CME. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Horizon CME.